Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU1-94P refers to a member of the large family of U1 small nuclear RNA pseudogenes, which are imperfect or variant copies of the canonical U1 small nuclear RNA gene, often termed pseudogenes due to sequence changes, deletions, or insertions that typically prevent the expression of fully functional U1 snRNA[2]. RNU1-94P is a pseudogene corresponding to a variant of the U1 small nuclear RNA gene family. U1 small nuclear RNA (snRNA) is an essential structural RNA component of the spliceosome—a ribonucleoprotein complex responsible for recognizing splice sites and initiating splicing of pre-mRNA in eukaryotic nuclei[1][2][3]. While canonical forms like "RNU1-1" encode functional U1 snRNA, pseudogenes like RNU1-94P generally contain sequence changes or deletions that impair canonical function. Some U1 pseudogenes can still be transcribed and may produce variant snRNAs which, in rare cases, modulate RNA processing in developmentally regulated or cell-specific contexts[2]. However, RNU1-94P itself is not known to encode a functional protein or RNA with a defined biological role, nor is it a receptor, enzyme, transporter, or conventional drug target. Key points: Not a classical drug target: RNU1-94P is a non-coding pseudogene, not a protein, receptor, or enzyme. Function uncertain: Some pseudogenes can affect gene regulation, but RNU1-94P lacks evidence for a defined biological or disease role[2]. Misspelling or missing information: "RNA, U1 small nuclear 94, pseudogene" is an accurate locus name for a pseudogene, but might be misinterpreted as a protein or active therapeutic target, which it is not[2].
Not applicable; no mechanism of drug action established for RNU1-94P.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U1 small nuclear 94, pseudogene (RNU1-94P).